Industry News

• Kura Oncology reports clinical activity of tipifarnib in subsets of pancreatic cancer  Kura Oncology reported new findings identifying a potential association between CXCL12 expression and clinical benefit in patients with pancreatic cancer treated with tipifarnib. A total of 688 patients were enrolled in study INT-11, of whom 155 reported no abdominal pain at study entry.
  January 18, 2019  
• Stemline Therapeutics closes $92 million public offering of common stock  Stemline Therapeutics announced the closing of a previously announced underwritten public offering of 10,222,222 shares of its common stock, which included the exercise in full of the option to purchase 1,333,333 additional shares, at a price of $9.00 per share.
  January 18, 2019  
• Liver cancer patients can be treated for Hep C infection  A large Southwestern Medical Center multi-center study refutes earlier suggestions that antiviral drugs for treating hepatitis C may lead to a higher recurrence of liver cancer. The study was published in the journal Gastroenterology.
  January 18, 2019  
• Kindred Biosciences announces pricing of public offering  Kindred Biosciences announced pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for gross proceeds of $40,042,500. KindredBio granted underwriters a 30-day option to purchase up to an additional 632,250 shares.
  January 18, 2019  
• Racial differences in Alzheimer’s disease unveiled  a new study from Washington University School of Medicine has identified racial disparities between African-Americans and Caucasians in the level of a key biomarker used to identify Alzheimer’s disease. The findings were published in JAMA Neurology.
  January 18, 2019  
• CVS Health and Walmart announce new PBM pharmacy network agreement  CVS Health and Walmart announced a multi-year agreement on terms under which Walmart will continue participating in the CVS Caremark pharmacy benefit management commercial and Managed Medicaid retail pharmacy networks. The financial terms of the new contract were not disclosed.
  January 18, 2019  
• Precision Therapeutics receives $1,370,000 investment from CEO Carl Schwartz  Precision Therapeutics announced that its CEO and director, Carl Schwartz, has made an additional investment of $1,000,000 in the Company. Of this investment, $950,000 was a loan under an amended and restated promissory note.
  January 18, 2019  
• FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for type 1 diabetes  The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted eight to eight on the question of whether the overall benefits of Zynquista™* (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor.
  January 17, 2019  
• Sunesis announces pricing of $20 million offering of securities  Sunesis Pharmaceuticals announced the pricing of underwritten public offerings of 23,000,000 shares of its common stock and 17,000 shares of its non-voting Series E Convertible Preferred Stock. The public offering price of each share of common stock is $0.50.
  January 17, 2019  
• Japanese Red Cross Society selects Abbott technology to screen country's blood and plasma   Abbott announced it has been selected by the Japanese Red Cross Society to partner in screening the country's blood donations. The 8-year contract is for the exclusive supply of serological instrumentation, tests and consumables used for blood and plasma screening.
  January 17, 2019  

   (next 10 articles)